Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Arthritis & Rheumatism

• Publication date

  2003-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ART.11033PMID 12687569
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An alternate-day corticosteroid regimen in maintenance therapy of giant cell arteritis.

  2009cited by this paper
• Treatment with infliximab restores normal aquaporin 5 distribution in minor salivary glands of patients with Sjögren's syndrome.

  2002cited by this paper
• Apoptosis and cellular vitality: issues in osteoarthritic cartilage degeneration.

  2002cited by this paper
• A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.

  2002cited by this paper
• Selective Down-Regulation of Aquaporin-1 in Salivary Glands in Primary Sjögren’s Syndrome

  2002cited by this paper
• Kinetics of the Ultrastructural Changes in Apoptotic Chondrocytes from an Osteoarthrosis Rat Model: A Window of Comparison to the Cellular Mechanism of Apoptosis in Human Chondrocytes

  2002cited by this paper
• Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment.

  2002cited by this paper
• The neural network as a predictor of cancer in patients with inflammatory myopathies.

  2002cited by this paper
• Criteria for TUNEL labeling in determining apoptosis in human osteoarthritis cartilage: Comment on the article by Aigner et al.

  2002cited by this paper
• Human chondrocyte senescence and osteoarthritis

  2002cited by this paper
• In vitro model for the study of necrosis and apoptosis in native cartilage

  2002cited by this paper
• Infliximab in patients with primary Sjögren's syndrome: a pilot study.

  2001cited by this paper
• Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.

  2001cited by this paper
• Improved differentiation between Churg-Strauss syndrome and Wegener's granulomatosis by an artificial neural network.

  2001cited by this paper
• Incidence of Malignant Disease in Biopsy-Proven Inflammatory Myopathy: A Population-Based Cohort Study

  2001cited by this paper
• Autoantibodies in Primary Sjögren's Syndrome: New Insights into Mechanisms of Autoantibody Diversification and Disease Pathogenesis

  2001cited by this paper
• Etanercept-induced subacute cutaneous lupus erythematosus.

  2001cited by this paper
• Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study.

  2001cited by this paper
• Apoptotic cell death is not a widespread phenomenon in normal aging and osteoarthritis human articular knee cartilage: a study of proliferation, programmed cell death (apoptosis), and viability of chondrocytes in normal and osteoarthritic human knee cartilage.

  2001cited by this paper
• Subcellular distribution of aquaporin 5 in salivary glands in primary Sjögren's syndrome.

  2001cited by this paper
• Is early rheumatoid arthritis the same disease process as late rheumatoid arthritis?

  2001cited by this paper
• Sarcoidosis: immunology, rheumatic involvement, and therapeutics.

  2001cited by this paper
• A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).

  2001cited by this paper
• Identification and localization of aquaporin water channels in human salivary glands.

  2001cited by this paper
• Office-based arthroscopic synovectomy of the wrist in rheumatoid arthritis.

  2001cited by this paper
• Long-Term Outcome of AntiGlomerular Basement Membrane Antibody Disease Treated with Plasma Exchange and Immunosuppression

  2001cited by this paper
• Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone

  2001cited by this paper
• The bone and joint decade: a catalyst for progress.

  2001cited by this paper
• Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies.

  2000cited by this paper
• Lessons learnt from the synovial tissue response to anti-rheumatic treatment.

  2000cited by this paper
• Apoptotic chondrocytes from osteoarthrotic human articular cartilage and abnormal calcification of subchondral bone.

  2000cited by this paper
• Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome.

  2000cited by this paper
• Tumor necrosis factor α blockers and the induction of anti‐DNA autoantibodies

  2000cited by this paper
• Etanercept Therapy in Rheumatoid Arthritis

  1999cited by this paper
• An Alternative Perspective to the Immune Response in Autoimmune Exocrinopathy: Induction of Functional Quiescence Rather Than Destructive Autoaggression

  1999cited by this paper
• Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

  1999cited by this paper
• Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis. French Vasculitis Study Group.

  1999cited by this paper
• Prediction Equation for Glomerular Filtration Rate

  1999cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Leflunomide for active rheumatoid arthritis.

  1999cited by this paper
• Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

  1997cited by this paper
• Synovial membrane inflammation and cytokine production in patients with early osteoarthritis.

  1997cited by this paper
• Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity.

  1997cited by this paper
• Tumor Necrosis Factor‐α Regulates Nicotinic Responses in Mixed Cultures of Sympathetic Neurons and Nonneuronal Cells

  1995cited by this paper
• Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study.

  1995cited by this paper
• Chondrocyte apoptosis in endochondral ossification of chick sterna

  1995cited by this paper
• Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome.

  1994cited by this paper
• Takayasu arteritis.

  1994cited by this paper
• Visual prognosis in giant cell arteritis.

  1993cited by this paper
• Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen.

  1992cited by this paper
• Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.

  1983cited by this paper
• The therapeutic impact of temporal artery biopsy.

  1983cited by this paper
• Mechanical properties and functions of the myoepithelium in the eccrine sweat gland.

  1979cited by this paper
• Skip lesions in temporal arteritis.

  1976cited by this paper
• Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study.

  1975cited by this paper

• TNF-Induced Lupus. A Case-Based Review.

  2021cites this paper
• PRACTICAL MANAGEMENT of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI).

  2021cites this paper
• Drug-induced lupus erythematosus.

  2020cites this paper
• Síndrome de activación macrofágica en adultos con enfermedad reumática

  2016cites this paper
• Macrophage activation syndrome in adults with rheumatic disease

  2016cites this paper
• Hair Loss Induced by Tumor Necrosis Factor Alpha Inhibitors

  2014cites this paper
• Lupus eritematoso inducido por fármacos

  2014cites this paper
• Etanercept‐induced Wegener granulomatosis in a patient with rheumatoid arthritis

  2013cites this paper
• Therapeutic blockade of TNF in patients with SLE-promising or crazy?

  2012cites this paper
• Etanercept: efficacy and safety for approved indications

  2012cites this paper
• Etanercept-Induced Lupus Panniculitis with Continued Improvement after Treatment with Adalimumab for Psoriatic Arthritis

  2012cites this paper
• Broad range of adverse cutaneous eruptions in patients on TNF‐alpha antagonists

  2012cites this paper
• Terapia biolgica en el lupus eritematoso sistmico. Hay vida ms all del linfocito B

  2011cites this paper
• [TNF-alpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunologic effects].

  2011cites this paper
• [Anti-TNFalpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies].

  2011cites this paper
• TNF alpha antagonist therapy and safety monitoring.

  2011cites this paper
• Etanercept-induced lupus accompanied by hemophagocytic syndrome.

  2011cites this paper
• A randomized, pilot trial of etanercept in dermatomyositis

  2011cites this paper
• Anticytokine therapies in systemic lupus erythematosus.

  2010cites this paper
• Acrylamine-induced autoimmune phenomena

  2010cites this paper
• Drug-induced subacute cutaneous lupus erythematosus

  2010cites this paper
• Cutaneous lupus erythematosus and anti-TNF-alpha therapy: a case report with review of the literature.

  2010cites this paper
• Anti-TNF-induced lupus.

  2009cites this paper
• A Mechanism-Based Classification of Dermatologic Reactions to Biologic Agents Used in the Treatment of Cutaneous Disease: Part 2

  2009cites this paper
• Antibody-based therapies in systemic lupus erythematosus.

  2009cites this paper
• Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies.

  2009cites this paper
• Medikamenteninduzierter Lupus erythematodes tumidus unter Adalimumab-Therapie

  2009cites this paper
• Biologic Therapies for Inflammatory Disease

  2008cites this paper
• Drug-induced arthritic and connective tissue disorders.

  2008cites this paper
• Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents

  2008cites this paper
• The role of tumor necrosis factor-alpha in systemic lupus erythematosus

  2008cites this paper
• The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment.

  2008cites this paper
• Novel immunobiologics for psoriasis

  2008cites this paper
• Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus.

  2008cites this paper
• Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus

  2008cites this paper
• Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab

  2008cites this paper
• [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].

  2008cites this paper
• Efalizumab-induced lupus-like syndrome.

  2008cites this paper
• From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.

  2008cites this paper
• Cutaneous adverse effects of biological therapies for psoriasis.

  2008cites this paper
• Drug-induced lupus due to anti-tumor necrosis factor alpha agents.

  2008cites this paper
• Drug-induced lupus erythematosus

  2008cites this paper
• Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept.

  2008cites this paper
• The safety of etanercept for the treatment of plaque psoriasis

  2007cites this paper
• Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases

  2007cites this paper
• Review of Medications Used in Juvenile Rheumatoid Arthritis

  2007cites this paper
• 37 - Drugs that act on the immune system: Cytokines and monoclonal antibodies

  2007cites this paper
• Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.

  2007cites this paper
• Immunobiologics in the treatment of psoriasis.

  2007cites this paper
• Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis

  2007cites this paper
• [AntiTNFalpha-induced systemic vasculitis and autoimmune disorders].

  2006cites this paper
• A medical bioinformatics approach for metabolic disorders: Biomedical data prediction, modeling, and systematic analysis

  2006cites this paper
• [A case of recurrent breast cancer with life-threatening multiple lung metastasis markedly responding to CMF as third-line chemotherapy].

  2006cites this paper
• Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.

  2006cites this paper
• Cutaneous lupus erythematosus: A personal approach to management

  2006cites this paper
• Etanercept and methotrexate for the treatment of rheumatoid arthritis

  2006cites this paper
• Lessons for lupus from tumour necrosis factor blockade.

  2006cites this paper
• Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.

  2006cites this paper
• Etanercept-Induced Systemic Lupus Erythematosus in a Patient with Rheumatoid Arthritis

  2006cites this paper
• Lessons for lupus from tumour necrosis factor blockade

  2006cites this paper
• Vascularites systémiques, syndromes auto-immuns et inhibiteurs du TNFalpha

  2006cites this paper
• Use of etanercept in the treatment of psoriasis and psoriatic arthritis.

  2006cites this paper
• Guidelines Update on the British Society for Rheumatology guidelines for prescribing TNF a blockers in adults with rheumatoid arthritis ( update of previous guidelines of April 2001 )

  2005cites this paper
• Anti-TNF Biological Agents in Rheumatoid Arthritis and Other Inflammatory Diseases

  2005cites this paper
• Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab.

  2005cites this paper
• Terapia con anti-TNFα in pazienti con artrite reumatoide e anticorpi anti-Ro/SSA* Anti-TNFα treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies

  2005cites this paper
• Current state of tumour necrosis factor α blockade in Wegener’s granulomatosis

  2005cites this paper
• Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).

  2005cites this paper
• Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment

  2005cites this paper
• Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study

  2005cites this paper
• Infliximab induced chilblain lupus in a patient with rheumatoid arthritis.

  2005cites this paper
• Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.

  2005cites this paper
• Lupus erythematosus manifestations exacerbated by etanercept therapy in a patient with mixed connective tissue disease.

  2005cites this paper
• Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

  2005cites this paper
• Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.

  2005cites this paper
• Infliximab-induced lupus or rheumatoid arthritis (RA) overlapping with systemic lupus erythematosus (SLE) unmasked by infliximab.

  2004cites this paper
• Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.

  2004cites this paper
• In silico systems analysis of biopathways

  2004cites this paper
• Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

  2004influential citation
• Drug-induced autoimmunity.

  2004cites this paper
• Anti-TNFα therapy in rheumatoid arthritis and autoimmunity

  2004cites this paper
• Drug-Induced Respiratory Disease in Connective Tissue Diseases

  2004cites this paper
• Vascularite cutanée et glomérulonéphrite chez une polyarthrite rhumatoïde (PR) traitée par anti-TNFα (étanercept)

  2004cites this paper
• Accumulation of plasma nucleosomes upon treatment with anti‐tumour necrosis factor‐α antibodies

  2004cites this paper
• Lupus erythematosus with leflunomide: induction or reactivation?

  2004cites this paper
• Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies.

  2004cites this paper
• A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab

  2004cites this paper
• Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis.

  2004cites this paper
• Pharmacoepidemiology and drug safety.

  2003cites this paper
• [TNF alpha-antagonists in collagen vascular disease].

  2003cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2003cites this paper
• Gibt es eine Indikation für TNFα-Antagonisten bei Kollagenosen?

  2003cites this paper